Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation

NCT03314064 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03314064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03314064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
December 8, 2016
Completion date
October 1, 2018
Enrollment
43 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, infection, human immunodeficiency virus